Memantina Aurovitas Spain

Memantine, the active ingredient in Memantina Aurovitas Spain, is a NMDA receptor antagonist presented as an oral tablet for oral use. It treats Alzheimer’s disease in adults, helping to improve cognition and functional abilities.

GNH USA supplies Memantina Aurovitas Spain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable distribution across global markets.

Memantine is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting memory and cognition.

- Mild to moderate Alzheimer’s disease: may help maintain cognitive function and delay functional decline. - Moderate to severe Alzheimer’s disease: supports daily functioning and slows progression of symptoms. - Behavioral disturbances in Alzheimer’s disease: can reduce agitation and improve overall patient behavior.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial discomfort. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness or lack of energy. - Confusion: occasional mental clouding. - Hypertension: slight increase in blood pressure.

Serious or Rare Side Effects: - Seizures: rare occurrence of convulsive episodes. - Cardiac arrhythmia: irregular heart rhythm that may require monitoring. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Hepatic dysfunction: abnormal liver enzyme elevations.

Memantine should be used with caution in the following situations: - Renal impairment: dose adjustment may be required. - Hepatic impairment: monitor liver function tests. - History of seizures: increased risk of convulsions. - Elderly patients: watch for confusion or falls. - Concomitant NMDA antagonists: avoid combined use. - Store at below 25°C: keep in the original pack, protect from moisture.

Memantine may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase adverse effects. - Dextromethorphan: combined use can enhance neuropsychiatric reactions. - Ketamine: concurrent NMDA blockade may lead to excessive CNS depression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefits. - CNS depressants (e.g., benzodiazepines): increased sedation risk. - Diuretics: possible alteration of serum memantine levels.